Tamtam Try Tamtam free
Medicover logo

Medicover account plan

International healthcare and diagnostic services

At a glance

Medicover is a Stockholm-listed healthcare and diagnostics group in Central and Eastern Europe, with FY2025 revenue of €2,378.1m and 49,409 co-workers.

Medicover is a healthcare services and diagnostics group founded in 1995 and listed on Nasdaq Stockholm since 2017, operating clinics, hospitals, dental and fertility clinics, gyms, laboratories and blood-drawing points. Its primary markets are Poland, Germany and Romania, with Poland 52% of FY2025 revenue, and 79% of group revenue comes from private pay (employer-funded plans and fee-for-service). FY2025 revenue was €2,378.1m (+13.7%, organic 12.7%), EBITDA €371.0m (15.6% margin) and profit for the year €72.7m, with 49,409 co-workers. In August 2026 it agreed to sell its Indian hospitals to funds managed by KKR. Celox Holding AB holds 56.0% of the votes.

Business units

Strategic priorities

2026-2028 financial targets
Organic revenue above €3.25bn and adjusted organic EBITDA above €600m by 2028, leverage of 3.0x or less and a payout of up to 50%, unchanged until the India sale closes.
Refocus on three European markets
Proceeds of approximately EUR 0.74bn from the India sale are to accelerate strategy execution in Poland, Germany and Romania.
Expand the service offering
Grow speciality care (hospitals, dental, mental health, orthopaedics, sports and wellness) and advanced diagnostics; in Poland Medicover has consolidated only about 5% of the dental market and plans more hospitals.
Operational excellence
Procurement savings, a hub-and-spoke laboratory network on a proprietary laboratory information system, higher capacity utilisation and technology to cut doctors' administrative work.
Digital differentiation
Apps, telemedicine, digital triage and AI, including voice recognition and automated medical records, described as central to running and growing the business.
Selective M&A and consolidation
86 acquisitions since the 2017 IPO; the CEO expects further consolidation in Poland and Romania as competitors reliant on public funds struggle.

Latest results

In Q3 2026 (continuing operations, India excluded), revenue rose 6.0% to EUR 570.8 million with organic growth of 8.0% and a 2.0% currency drag; EBIT grew 22.0% to EUR 49.3 million at an 8.6% margin, and net profit was EUR 24.8 million. It was the seventh consecutive quarter of year-on-year margin improvement. Over nine months, revenue was EUR 1,721.6 million (+6.4%, organic +8.5%). Leverage fell to 2.7x from 3.1x at end 2025, and a new EUR 450.0 million RCF was signed. Management flags near-term softness in public reimbursement, a German genetics reform from October 2026, and slower B2B membership.

Investments and deals

SYNLAB businesses acquisition
Completed in 2025 in Romania, Turkey, Cyprus, Slovenia, Croatia and North Macedonia: 30 laboratories, 100 blood-drawing points and over 600 professionals.
CityFit gym chain
Acquired in 2025 in Poland: 26 clubs and nearly 130,000 active members; 16 new fitness facilities opened in 2026 so far, with openings set to accelerate.
Sale of Medicover Hospitals India
A EUR 1.2 billion transaction with funds managed by KKR announced 6 August 2026; Medicover's 66.1% stake brings about EUR 740 million and should leave it debt-free.
Capex and network reshaping
Capex in PP&E and intangibles was €158.1m in 2025; full-year 2026 capex is guided at 6-6.5% of revenue, and 118 facilities were closed while over 140 opened in twelve months.
Medicover Genetics MRD test
A blood-based minimal residual disease test for lung cancer recurrence, launched in 2026, detects issues 7.4 months earlier than traditional methods.

Challenges and risks

Public reimbursement cuts
German laboratory reimbursement fell from 1 January 2025, a German genetics reform took effect in October 2026, and Romania brought caps and tariff cuts in public healthcare.
Medical workforce shortage
Rated a High risk in the 2025 risk register; inflation-driven medical salary increases weigh on Polish inpatient margins.
Geopolitical and data risks
Armed conflict (Ukraine) and data loss or breach are the other two risks rated High.
Slower B2B membership
Members fell to 1,487K in Q3 2026 from 1,549K, mainly in Romania, after pricing decisions and slower employer hiring.

What leadership says

“maybe we kept our prices a little bit too high for a little bit too long, and we need to repurpose or make adjustments, which we've done.”

John Stubbington, CEO · Q3 2026 earnings call (2026-11-04)

“The Indian divestment brings us EUR 740 million, and we will focus that money on our core countries.”

John Stubbington, CEO · Q3 2026 earnings call (2026-11-04)

“First and foremost, you need scale in healthcare. That's why our number one strategic priority remains growth.”

John Stubbington, CEO · Warsaw Business Journal interview (2025-08-25)

“We've all seen doctors typing with one finger”

John Stubbington, CEO · Warsaw Business Journal interview, on efficiency (2025-08-25)

Where a supplier can help

Clinical documentation and AI
The efficiency priority of freeing doctors from administrative work, with voice recognition and automated medical records, opens room for clinical AI and documentation tools.
Laboratory automation
Consolidation and automation are Medicover's answer to German reimbursement cuts, a fit for lab automation, LIS and logistics suppliers.
Fit-out for new gyms, clinics and hospitals
Accelerated gym openings, planned Polish hospitals and over 140 new facilities in twelve months create demand for equipment, construction and facility services.
Post-acquisition integration
The SYNLAB integration and expected further consolidation, funded by the India proceeds, call for integration, IT migration and procurement support.
Workforce and data security
Workforce shortage and data breach risks, both rated High, point to recruiting, retention and cyber security offerings.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Medicover?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Medicover

What does Medicover do?

Medicover runs healthcare services (clinics, hospitals, dental, fertility, gyms) and diagnostic laboratories, mainly in Poland, Germany and Romania, funded mostly by private pay.

What is Medicover's revenue?

FY2025 revenue was €2,378.1m, up 13.7%, with EBITDA of €371.0m. Q3 2026 revenue from continuing operations was EUR 570.8 million.

How many employees does Medicover have?

49,409 co-workers at end of 2025.

Who leads Medicover?

John Stubbington has been CEO since 1 May 2025, Anand Patel is CFO, and Fredrik Stenmo chairs the board.

Why is Medicover selling its Indian hospitals?

The sale to funds managed by KKR brings about EUR 740 million for Medicover's 66.1% stake, to be focused on Poland, Germany and Romania.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)